We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00675077
First Posted: May 8, 2008
Last Update Posted: January 5, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
GAAD Medical Research Institute Inc.
May 6, 2008
May 8, 2008
January 5, 2009
May 2008
May 2010   (Final data collection date for primary outcome measure)
Treatment of people with HD [ Time Frame: 2 years ]
Same as current
Complete list of historical versions of study NCT00675077 on ClinicalTrials.gov Archive Site
Rehabilitation of people with HD [ Time Frame: 2 Years ]
Same as current
Not Provided
Not Provided
 
Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.

This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.

Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Huntington Disease
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation (5μm to 20μm wavelength)
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Intervention: Radiation: Far Infrared Radiation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
5
June 2010
May 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • People with HD

Exclusion Criteria:

Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00675077
GAAD-HD-CTP1
Yes
Not Provided
Not Provided
Dr. Kwasi Donyina/Founder & President, GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
Not Provided
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP